Bridging Quantum and Classical Computing in Drug Design: Architecture Principles for Improved Molecule Generation
Hybrid quantum-classical machine learning offers a path to leverage noisy intermediate-scale quantum (NISQ) devices for drug discovery, but optimal model architectures remain unclear. We systematically optimize the quantum-classical bridge architecture for generative adversarial networks (GANs) in molecular discovery using multi-objective Bayesian optimization. Our optimized model (BO-QGAN) significantly improves performance, achieving a 2.27-fold higher Drug Candidate Score (DCS) than prior quantum-hybrid benchmarks and 2.21-fold higher than the classical baseline, using over 60% fewer parameters. Key findings favor layering multiple (3-4) shallow (4-8 qubit) quantum circuits sequentially, while classical architecture shows less sensitivity above a minimum capacity. This work provides the first empirically grounded architectural guidelines for hybrid models, enabling more effective integration of current quantum computers into pharmaceutical research pipelines.
Code (1)
Tasks
Bayesian OptimizationDrug DesignDrug DiscoverySimilar Papers 제목 키워드 기반
Scalable Variational Quantum Circuits for Autoencoder-based Drug Discovery
The de novo design of drug molecules is recognized as a time-consuming and costly process, and computational approaches have been applied in each stage of the drug discovery pipeline. Variational autoencoder is one of th…
Drug DiscoveryQuantum Machine LearningRepresentation LearningLatent Style-based Quantum Wasserstein GAN for Drug Design
The development of new drugs is a tedious, time-consuming, and expensive process, for which the average costs are estimated to be up to around $2.5 billion. The first step in this long process is the design of the new dr…
Drug DiscoveryThe Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery
Integrating quantum mechanics into drug discovery marks a decisive shift from empirical trial-and-error toward quantitative precision. However, the prohibitive cost of ab initio molecular dynamics has historically forced…
Drug DiscoveryHybrid quantum-classical machine learning for generative chemistry and drug design
Deep generative chemistry models emerge as powerful tools to expedite drug discovery. However, the immense size and complexity of the structural space of all possible drug-like molecules pose significant obstacles, which…
Drug DesignDrug DiscoveryQuantum Computing-Enhanced Algorithm Unveils Novel Inhibitors for KRAS
The discovery of small molecules with therapeutic potential is a long-standing challenge in chemistry and biology. Researchers have increasingly leveraged novel computational techniques to streamline the drug development…
Drug Discovery